RxDoctor Payments Data

James Amara

Family · Bowie, MDNPI 1114671880

Payments from drug & device makers

$2,129in general payments, 2019–2025

Across 85 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$250
  • Boehringer Ingelheim$236
  • Vifor Pharma, Inc.$186
  • Novartis$166
  • Novo Nordisk$156
  • Bayer$148
  • plus $986 from 13 others

What the payments were for

  • Food & beverage$2,10499%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,129 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$8,143
Medicare patients
49
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$9,358
Sevelamer Carbonate32$7,304
Calcium Acetate36$3,039
Hydralazine Hcl27$428
Amlodipine Besylate47$374
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide13$362
Atorvastatin Calcium16$253
Lidocaine-PrilocaineLidocaine/Prilocaine11$245
Furosemide37$233
Pantoprazole Sodium14$228
Losartan Potassium27$220
Spironolactone41$211
Nifedipine ErNifedipine12$201
ClopidogrelClopidogrel Bisulfate12$189
Triamcinolone Acetonide13$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$123$9,35811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →